ORIXHA Secures $12M in Series A to Accelerate Vent2Cool, Revolutionizing Critical Care through Liquid Ventilation

ORIXHA is thrilled to announce a successful funding round, having raised a remarkable $12,000,000 to further its groundbreaking mission of saving patients' lives in critical care through innovative liquid ventilation technology. This significant infusion of capital underscores the confidence investors have in ORIXHA’s vision and the revolutionary impact their flagship product, the Vent2Cool, is poised to make in emergency medical care. The Vent2Cool is an ingenious medical device designed to almost immediately protect vital organs—most notably the brain and heart—of patients resuscitated after cardiac arrest. By effectively turning the lungs into a sophisticated heat exchanger with the blood compartment, the device orchestrates ultra-rapid therapeutic hypothermia, reducing the time required to reach the target temperature of 33°C from several hours to just a few minutes. This accelerated cooling is critical in mitigating the damage that can lead to significant mortality and morbidity following a cardiac event, thus heralding a new era in emergency medicine and intensive care. The fresh capital will be strategically allocated to advancing the clinical trials and regulatory pathway for Vent2Cool, expanding research and development efforts, and scaling production capabilities to meet future market demands. By accelerating the journey from technical innovation to widespread clinical application, ORIXHA is dedicated to transforming the landscape of post-cardiac arrest care, ultimately saving more lives and reducing long-term neurological damage in critical patients. This funding milestone not only validates ORIXHA's cutting-edge approach but also marks a pivotal step toward revolutionizing critical care treatment through rapid therapeutic intervention. The future of emergency medical response is here, and ORIXHA stands at the forefront of this vital transformation.